Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06119373
Other study ID # IIT-2022-0224
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 1, 2023
Est. completion date November 30, 2026

Study information

Verified date November 2023
Source RenJi Hospital
Contact Hao Yan, MD.
Phone 0086-13816588689
Email dryanhao@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objectives: To investigate the efficacy and safety of single daily icodextrin exchange for initiation of incremental peritoneal dialysis (PD). Subjects: Seventy-two incident PD patients. Methods: A single-center randomized controlled trial. Primary outcome: Change in residual kidney function in 48 weeks after recruitment.


Description:

Incremental peritoneal dialysis (PD) has become a more prevalently adopted strategy in incident PD patients. There is significant variation in regimens of incremental PD. Initiation of PD with a single daily icodextrin exchange in patients with considerable residual kidney function is able to achieve successful water, sodium removal and solute clearance, while it has not been investigated and validated in randomized controlled trials. This single-center, randomized, controlled study is to compare the effects of two prescriptions for initiation of incremental PD, a single daily icodextrin exchange versus 2-3 exchanges of glucose-based dialysate, on patients' residual kidney function, survival, peritonitis, and quality of life, in order to develop a new paradigm of incremental PD. The primary outcome is change of residual kidney function, and the secondary outcomes include mortality, peritonitis-free survival, health-related quality of life, volume status, adequacy of small molecular solute clearance, and glucose exposure to dialysate. Seventy-two eligible incident PD patients will be enrolled and randomly assigned to either the experimental or the control group in a ration of 1:1. Patients of the experimental group initiate PD with once daily exchange of 2-liter icodextrin dialysate, while those of the control group initiate PD with 2 to 3 exchanges of 2-liter glucose-based dialysate per day. All the enrolled patients will be prospectively followed up for 48 weeks. During the follow-up, the dose of dialysis would be incremental increased by adding exchange of glucose-based solution as required to accommodate for decline of RKF when at least one of the following indications is met: (1) clinical manifestations of uremia due to insufficient small solute clearance; (2) fluid overload which could not be corrected by salt and water intake restriction, increasing glucose concentration of dialysate, and administration of diuretics. Residual kidney function, urine volume, peritoneal ultrafiltration, biochemical parameters, dialysate glucose exposure, volume status (measured by bioimpedence), and solute clearance are measured at baseline, and 24 and 48 weeks after recruitment, and are compared between groups. Quality of life is evaluated at baseline and 48 weeks by Kidney Disease Quality of Life-Short Form (KDQoL-SF) questionnaire, and are compared between two groups. Peritonitis rate for both groups are calculated and peritonitis-free survivals are compared. Differences in outcomes are evaluated by t test, Mann-Whitney test, or log-rank test where appropriate.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 72
Est. completion date November 30, 2026
Est. primary completion date May 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. male or female patients aged 18 to 75 years; 2. patients with chronic kidney disease stage 5 who are to start PD; 3. eGFR = 5 ml/min; 4. urine output = 800 ml/d. Exclusion Criteria: 1. documented anaphylaxis with icodextrin or glucose-based dialysate; 2. concomitant severe chronic diseases such as malignancy, hepatitis, severe cardiac diseases, etc.; 3. ongoing severe infection; 4. planned or ongoing pregnancy or lactation; 5. currently enrolled in other clinical studies; 6. patients who have a life expectancy of <12 months; 7. refusal to give a written consent.

Study Design


Intervention

Other:
Single daily icodextrin exchange
PD initiation with single daily exchange of 2-liter icodextrin-based dialysis solution.
Conventional PD group
PD is initiated with 2 to 3 exchanges of 2-liter glucose-based dialysis solution.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
RenJi Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Residual kidney function Change of residual kidney function in 48 weeks after PD initiation Up to 48 weeks after recruitment
Secondary Mortality The endpoint was death. The censored events include transfer to permanent hemodialysis, recovery of renal function, loss to follow-up, transfer to other dialysis centers, or to the end of study. Up to 48 weeks after recruitment
Secondary Peritonitis-free survival The endpoint was first episode of PD-related peritonitis. The censored events were death, transfer to permanent hemodialysis, recovery of renal function, loss to follow-up, transfer to other dialysis centers, or to the end of study. Up to 48 weeks after recruitment
Secondary Health-related quality of life Change of health-related quality of life assessed using Kidney Disease Quality of Life-Short Form in 48 weeks after recruitment. The form generates a score of 0 to 100, which represents better quality of life by a higher value. Up to 48 weeks after recruitment
Secondary Volume status Change of volume status (Overhydration assessed by Bioelectric Impedance Analysis, etc.) in 48 weeks after recruitment Up to 48 weeks after recruitment
Secondary Adequacy of small molecular solute clearance Change of weekly Kt/V and clearance of creatinine assessed using standard methods in 48 weeks after recruitment Up to 48 weeks after recuritment
Secondary glucose exposure to dialysate change of glucose exposure to dialysate in 48 weeks after PD initiation Up to 48 weeks after recuritment
See also
  Status Clinical Trial Phase
Completed NCT01952184 - Oocyte Survival After Vitrification in an Open or Closed Device With Closed Storage. N/A
Completed NCT00993343 - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Phase 3
Recruiting NCT04808466 - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Not yet recruiting NCT04845490 - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT03291275 - Survival Outcomes of Uterine Malignancies in Chinese Population N/A
Recruiting NCT05720858 - Telerehabilitation in Survival Breast Cancer Patients N/A
Completed NCT03351920 - Ventilation's Parameters Applied in Emergency Medicine. A Prospective Observational Study
Not yet recruiting NCT06147180 - Comparison of Long-term Survival and Quality of Life After Minimally Invasive Esophagectomy Versus Open Esophagectomy
Recruiting NCT04472403 - Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
Recruiting NCT03739944 - Different Surgical Approaches in Patients of Early-stage Cervical Cancer Phase 3
Not yet recruiting NCT02960061 - Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer Phase 3
Recruiting NCT03738969 - Longitudinal Study of Different Surgical Approaches in Chinese Patients of Uterine Cervical Cancer
Completed NCT03134807 - The Very Old Intensive Care Patient: A Multinational Prospective Observation Study
Completed NCT03084809 - Chemotherapy Combined With CIK Treating Colon Cancer Phase 4
Completed NCT03642041 - Study of Smoking Trajectory in Newly Diagnosis Lung Cancer Patients
Recruiting NCT04351308 - Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma Phase 2
Recruiting NCT03920033 - Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy N/A
Recruiting NCT05540119 - Swedish Oesophago-Gastric Study
Completed NCT04519450 - Ultrasound of Accessory Respiratory Muscles
Active, not recruiting NCT01835821 - Clinical Study of Porcelain-fused and IPS e.Max CAD Crowns N/A